DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
47 hedge funds and large institutions have $5.79M invested in DMK Pharmaceuticals Corporation Common Stock in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
72% more capital invested
Capital invested by funds: $3.37M → $5.79M (+$2.42M)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
24% more funds holding
Funds holding: 38 → 47 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.06M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.83M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$58.3K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$53.5K |
| 5 |
Millennium Management
New York
|
+$32.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$15.5K |
| 2 |
Jane Street
New York
|
-$12K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.96K |
| 4 |
Morgan Stanley
New York
|
-$2.46K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$891 |
DMK Hedge Fund Activity: Q1 2020 in Review
47 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2020, worth a combined $5.79M — up 72% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DMK positions and 2 closed out — a net gain of 10 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $2.06M. The largest seller was Acadian Asset Management, cutting an estimated $15.5K.
- 47 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2020, up from 38 in Q4 2019.
- Funds reported $5.79M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2020, up 72% quarter-over-quarter.
- 12 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2020 and 2 closed out, a net change of +10 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2020 was CVI Holdings, an estimated $2.06M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2020 was Acadian Asset Management, an estimated $15.5K sold.
Based on aggregated 13F filings for Q1 2020.